Previous 10 | Next 10 |
MediWound Ltd. (MDWD) Q2 2022 Earnings Conference Call August 9, 2022 08:30 ET Company Participants Monique Kosse - Investor Relations Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Bryan Ber...
MediWound press release ( NASDAQ: MDWD ): Q2 GAAP EPS of -$0.13 misses by $0.03 . Revenue of $4.67M (-22.8% Y/Y) misses by $0.61M . For further details see: MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M
Positive Results in Two Phase 2 Trial s of EscharEx FDA Assigned PDUFA Target Date of January 1 , 202 3 for NexoBrid BLA Enhance d the Board and L eadership T eam Conference C all...
Mr. N achum Shamir appointed as Chairman of the Board Dr. Robert Snyder appointed as Chief Medical Officer YAVNE, Israel, Aug. 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated b...
MediWound ( NASDAQ: MDWD ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.10 (+16.7% Y/Y) and the consensus Revenue Estimate is $5.28M (-12.7% Y/Y). Over the last 1 year, MDWD has beaten EPS ...
The U.S. Food and Drug Administration (FDA) accepted for review MediWound's ( NASDAQ: MDWD ) re-submitted biologics license application (BLA) seeking approval of NexoBrid for eschar (dead tissue) removal (debridement) in adults with deep partial-thickness and/or full-...
YAVNE, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the U.S. Food and Drug Admini...
Call Scheduled for Tuesday, August 9, 2022 at 8:30 AM Eastern Time YAVNE, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, tod...
MW005 Shown to Be Safe and Well-Tolerated Target Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept YAVNE, Israel, July 11, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company ...
YAVNE, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced an oral presentation at the Advanced Wound Care Summit taking ...
News, Short Squeeze, Breakout and More Instantly...
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in ne...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...